There can be no guarantee that Exelon Patch will achieve any particular levels of revenue later on. essentially, Management's expectations regarding Exelon Patch could be affected by, amongst other things, uncontrolled clinical trial results, Including unanticipated new clinical data and unexpected additional analysis of existing clinical data; harmful regulatory actions or delays or government regulation generally; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; rivalry in general; military, Industry and community pricing pressures; Unexpected output issues; The impact that the foregoing factors could have on the values attributed to the Novartis Group's liabilities and assets as recorded in the Group's consolidated balance sheet, And other risks and factors seen by in Novartis AG's current Form 20 F on file with the US Securities and Exchange Commission. Should one or more of these risks or concerns materialize, Or should underlying presumptions prove incorrect, Actual results may vary materially from those estimated, reckoned, approximately or }